false 2019 Q1 0000921299 --12-31 Large Accelerated Filer 0 2019 us-gaap:ProductMember us-gaap:ProductMember P3Y4M24D P3Y7M6D P1Y10M24D P2Y1M6D P5Y8M12D P5Y3M18D P6M P6M P2Y P2Y 0.495 0.481 0.577 0.621 0.015 0.013 0.029 0.029 0000921299 2020-01-01 2020-03-31 xbrli:shares 0000921299 2020-04-30 iso4217:USD 0000921299 2020-03-31 0000921299 2019-12-31 iso4217:USD xbrli:shares 0000921299 us-gaap:LicenseMember 2020-01-01 2020-03-31 0000921299 us-gaap:LicenseMember 2019-01-01 2019-03-31 0000921299 fgen:DevelopmentAndOtherRevenueMember 2020-01-01 2020-03-31 0000921299 fgen:DevelopmentAndOtherRevenueMember 2019-01-01 2019-03-31 0000921299 us-gaap:ProductMember 2020-01-01 2020-03-31 0000921299 us-gaap:ProductMember 2019-01-01 2019-03-31 0000921299 2019-01-01 2019-03-31 0000921299 fgen:AstellasCollaborationAgreementMember 2020-01-01 2020-03-31 0000921299 fgen:AstellasCollaborationAgreementMember 2019-01-01 2019-03-31 0000921299 us-gaap:CommonStockMember 2019-12-31 0000921299 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000921299 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000921299 us-gaap:RetainedEarningsMember 2019-12-31 0000921299 us-gaap:NoncontrollingInterestMember 2019-12-31 0000921299 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000921299 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000921299 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000921299 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000921299 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0000921299 us-gaap:CommonStockMember 2020-03-31 0000921299 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000921299 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000921299 us-gaap:RetainedEarningsMember 2020-03-31 0000921299 us-gaap:NoncontrollingInterestMember 2020-03-31 0000921299 us-gaap:CommonStockMember 2018-12-31 0000921299 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000921299 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000921299 us-gaap:RetainedEarningsMember 2018-12-31 0000921299 us-gaap:NoncontrollingInterestMember 2018-12-31 0000921299 2018-12-31 0000921299 us-gaap:AccountingStandardsUpdate201602Member us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000921299 us-gaap:AccountingStandardsUpdate201602Member us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000921299 us-gaap:AccountingStandardsUpdate201602Member us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000921299 us-gaap:AccountingStandardsUpdate201602Member us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000921299 us-gaap:AccountingStandardsUpdate201602Member us-gaap:NoncontrollingInterestMember 2019-01-01 2019-03-31 0000921299 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 2019-03-31 0000921299 us-gaap:AccountingStandardsUpdate201802Member us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000921299 us-gaap:AccountingStandardsUpdate201802Member us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000921299 us-gaap:AccountingStandardsUpdate201802Member us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000921299 us-gaap:AccountingStandardsUpdate201802Member us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000921299 us-gaap:AccountingStandardsUpdate201802Member us-gaap:NoncontrollingInterestMember 2019-01-01 2019-03-31 0000921299 us-gaap:AccountingStandardsUpdate201802Member 2019-01-01 2019-03-31 0000921299 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000921299 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000921299 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000921299 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000921299 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-03-31 0000921299 us-gaap:CommonStockMember 2019-03-31 0000921299 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000921299 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000921299 us-gaap:RetainedEarningsMember 2019-03-31 0000921299 us-gaap:NoncontrollingInterestMember 2019-03-31 0000921299 2019-03-31 0000921299 country:JP 2020-01-01 2020-03-31 0000921299 srt:EuropeMember 2020-01-01 2020-03-31 0000921299 fgen:UnitedStatesRestOfWorldAndChinaMember 2020-01-01 2020-03-31 fgen:Segment 0000921299 country:JP fgen:AstellasCollaborationAgreementMember 2005-06-01 2009-02-28 0000921299 country:JP fgen:AstellasCollaborationAgreementMember 2005-06-01 2005-06-30 0000921299 country:JP fgen:AstellasCollaborationAgreementMember fgen:ClinicalDevelopmentMilestonesMember 2005-06-01 2005-06-30 0000921299 country:JP fgen:AstellasCollaborationAgreementMember fgen:RegulatoryMilestonesMember 2005-06-01 2005-06-30 0000921299 country:JP fgen:AstellasCollaborationAgreementMember 2020-01-01 2020-03-31 0000921299 country:JP fgen:AstellasCollaborationAgreementMember 2020-03-31 0000921299 srt:EuropeMember fgen:AstellasCollaborationAgreementMember 2006-04-01 2009-02-28 0000921299 srt:EuropeMember fgen:AstellasCollaborationAgreementMember 2006-04-30 0000921299 srt:EuropeMember fgen:AstellasCollaborationAgreementMember fgen:ClinicalDevelopmentMilestonesMember 2006-04-01 2006-04-30 0000921299 srt:EuropeMember fgen:AstellasCollaborationAgreementMember fgen:RegulatoryMilestonesMember 2006-04-01 2006-04-30 xbrli:pure 0000921299 srt:EuropeMember fgen:AstellasCollaborationAgreementMember 2006-04-01 2006-04-30 0000921299 srt:EuropeMember fgen:AstellasCollaborationAgreementMember 2020-01-01 2020-03-31 0000921299 srt:EuropeMember fgen:AstellasCollaborationAgreementMember 2020-03-31 0000921299 srt:EuropeMember fgen:AstellasCollaborationAgreementMember 2019-12-31 0000921299 fgen:UnitedStatesAndRestOfWorldMember fgen:AstraZenecaAgreementsMember 2013-07-29 2013-07-30 0000921299 fgen:UnitedStatesAndRestOfWorldMember fgen:ClinicalDevelopmentMilestonesMember fgen:AstraZenecaAgreementsMember 2013-07-29 2013-07-30 0000921299 fgen:UnitedStatesAndRestOfWorldMember fgen:RegulatoryMilestonesMember fgen:AstraZenecaAgreementsMember 2013-07-29 2013-07-30 0000921299 fgen:UnitedStatesAndRestOfWorldMember fgen:DeferredApprovalMilestoneMember fgen:AstraZenecaAgreementsMember 2013-07-29 2013-07-30 0000921299 fgen:UnitedStatesAndRestOfWorldMember fgen:DevelopmentMilestonesMember fgen:AstraZenecaAgreementsMember 2015-01-01 2015-12-31 0000921299 fgen:UnitedStatesAndRestOfWorldMember fgen:NewDrugApplicationSubmissionMilestoneMember fgen:AstraZenecaAgreementsMember us-gaap:SubsequentEventMember 2020-04-01 2020-04-30 0000921299 fgen:UnitedStatesAndRestOfWorldMember fgen:AstraZenecaAgreementsMember 2020-03-31 0000921299 fgen:AstraZenecaAgreementsMember 2019-06-30 0000921299 fgen:AstraZenecaAgreementsMember 2019-12-31 0000921299 fgen:AstraZenecaAgreementsMember 2020-03-31 0000921299 country:CN fgen:AstraZenecaAgreementsMember 2013-07-29 2013-07-30 0000921299 country:CN fgen:ClinicalDevelopmentMilestonesMember fgen:AstraZenecaAgreementsMember 2013-07-29 2013-07-30 0000921299 country:CN fgen:RegulatoryMilestonesMember fgen:AstraZenecaAgreementsMember 2013-07-29 2013-07-30 0000921299 country:CN fgen:AstraZenecaAgreementsMember 2020-03-31 0000921299 country:CN fgen:AstraZenecaAgreementsMember 2019-12-01 2019-12-31 0000921299 country:CN fgen:AstraZenecaAgreementsMember 2020-01-01 2020-03-31 0000921299 country:JP fgen:AstellasCollaborationAgreementMember us-gaap:LicenseMember 2020-01-01 2020-03-31 0000921299 country:JP fgen:AstellasCollaborationAgreementMember us-gaap:LicenseMember 2019-01-01 2019-03-31 0000921299 country:JP fgen:AstellasCollaborationAgreementMember fgen:DevelopmentAndOtherRevenueMember 2020-01-01 2020-03-31 0000921299 country:JP fgen:AstellasCollaborationAgreementMember fgen:DevelopmentAndOtherRevenueMember 2019-01-01 2019-03-31 0000921299 us-gaap:LicenseMember country:JP fgen:AstellasCollaborationAgreementMember 2020-03-31 0000921299 fgen:DevelopmentAndOtherRevenueMember country:JP fgen:AstellasCollaborationAgreementMember 2020-03-31 0000921299 srt:EuropeMember fgen:AstellasCollaborationAgreementMember us-gaap:LicenseMember 2020-01-01 2020-03-31 0000921299 srt:EuropeMember fgen:AstellasCollaborationAgreementMember us-gaap:LicenseMember 2019-01-01 2019-03-31 0000921299 srt:EuropeMember fgen:AstellasCollaborationAgreementMember fgen:DevelopmentAndOtherRevenueMember 2020-01-01 2020-03-31 0000921299 srt:EuropeMember fgen:AstellasCollaborationAgreementMember fgen:DevelopmentAndOtherRevenueMember 2019-01-01 2019-03-31 0000921299 us-gaap:LicenseMember srt:EuropeMember fgen:AstellasCollaborationAgreementMember 2020-03-31 0000921299 fgen:DevelopmentAndOtherRevenueMember srt:EuropeMember fgen:AstellasCollaborationAgreementMember 2020-03-31 0000921299 srt:EuropeMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember fgen:AstellasCollaborationAgreementMember 2020-03-31 0000921299 fgen:UnitedStatesRestOfWorldAndChinaMember us-gaap:LicenseMember fgen:AstraZenecaAgreementsMember 2020-01-01 2020-03-31 0000921299 fgen:UnitedStatesRestOfWorldAndChinaMember us-gaap:LicenseMember fgen:AstraZenecaAgreementsMember 2019-01-01 2019-03-31 0000921299 fgen:UnitedStatesRestOfWorldAndChinaMember fgen:DevelopmentAndOtherRevenueMember fgen:AstraZenecaAgreementsMember 2020-01-01 2020-03-31 0000921299 fgen:UnitedStatesRestOfWorldAndChinaMember fgen:DevelopmentAndOtherRevenueMember fgen:AstraZenecaAgreementsMember 2019-01-01 2019-03-31 0000921299 country:CN fgen:AstraZenecaAgreementsMember 2019-01-01 2019-03-31 0000921299 fgen:UnitedStatesRestOfWorldAndChinaMember us-gaap:LicenseMember fgen:AstraZenecaAgreementsMember 2020-03-31 0000921299 fgen:UnitedStatesRestOfWorldAndChinaMember fgen:CoDevelopmentInformationSharingAndCommitteeServicesMember fgen:AstraZenecaAgreementsMember 2020-03-31 0000921299 fgen:UnitedStatesRestOfWorldAndChinaMember fgen:ChinaPerformanceObligationMember fgen:AstraZenecaAgreementsMember 2020-03-31 0000921299 fgen:UnitedStatesRestOfWorldAndChinaMember fgen:AstraZenecaAgreementsMember 2020-03-31 0000921299 us-gaap:ProductMember fgen:ContractualSalesRebateMember 2020-01-01 2020-03-31 0000921299 us-gaap:ProductMember fgen:KeyAccountHospitalSalesRebateMember 2020-01-01 2020-03-31 0000921299 us-gaap:ProductMember fgen:TransferFeeDiscountMember 2020-01-01 2020-03-31 0000921299 fgen:ContractualSalesRebateMember 2020-01-01 2020-03-31 0000921299 fgen:PriceAdjustmentMember us-gaap:ProductMember 2019-12-31 0000921299 fgen:ContractualSalesRebateMember us-gaap:ProductMember 2019-12-31 0000921299 fgen:KeyAccountHospitalSalesRebateMember us-gaap:ProductMember 2019-12-31 0000921299 fgen:TransferFeeDiscountMember us-gaap:ProductMember 2019-12-31 0000921299 us-gaap:ProductMember 2019-12-31 0000921299 fgen:PriceAdjustmentMember us-gaap:ProductMember 2020-01-01 2020-03-31 0000921299 fgen:PriceAdjustmentMember us-gaap:ProductMember 2020-03-31 0000921299 fgen:ContractualSalesRebateMember us-gaap:ProductMember 2020-03-31 0000921299 fgen:KeyAccountHospitalSalesRebateMember us-gaap:ProductMember 2020-03-31 0000921299 fgen:TransferFeeDiscountMember us-gaap:ProductMember 2020-03-31 0000921299 us-gaap:ProductMember 2020-03-31 0000921299 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000921299 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000921299 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000921299 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000921299 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000921299 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000921299 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000921299 us-gaap:EquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000921299 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000921299 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000921299 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000921299 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000921299 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000921299 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000921299 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000921299 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000921299 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000921299 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000921299 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000921299 us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000921299 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000921299 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000921299 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000921299 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000921299 fgen:BondAndMutualFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000921299 fgen:BondAndMutualFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000921299 fgen:BondAndMutualFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000921299 fgen:BondAndMutualFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000921299 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000921299 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000921299 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000921299 us-gaap:EquitySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000921299 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000921299 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000921299 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000921299 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000921299 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000921299 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000921299 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000921299 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000921299 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000921299 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000921299 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000921299 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000921299 fgen:LeaseObligationsMember us-gaap:FairValueInputsLevel1Member 2020-03-31 0000921299 fgen:LeaseObligationsMember us-gaap:FairValueInputsLevel2Member 2020-03-31 0000921299 fgen:LeaseObligationsMember us-gaap:FairValueInputsLevel3Member 2020-03-31 0000921299 fgen:LeaseObligationsMember 2020-03-31 0000921299 fgen:LeaseObligationsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000921299 fgen:LeaseObligationsMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000921299 fgen:LeaseObligationsMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000921299 fgen:LeaseObligationsMember 2019-12-31 0000921299 2019-01-01 2019-12-31 0000921299 us-gaap:GeographicDistributionForeignMember 2020-03-31 0000921299 us-gaap:GeographicDistributionForeignMember 2019-12-31 0000921299 us-gaap:USTreasurySecuritiesMember 2020-03-31 0000921299 us-gaap:CertificatesOfDepositMember 2020-03-31 0000921299 us-gaap:EquitySecuritiesMember 2020-03-31 0000921299 us-gaap:USTreasurySecuritiesMember 2019-12-31 0000921299 us-gaap:CertificatesOfDepositMember 2019-12-31 0000921299 fgen:BondAndMutualFundsMember 2019-12-31 0000921299 us-gaap:EquitySecuritiesMember 2019-12-31 fgen:Milestone 0000921299 fgen:AstraZenecaAgreementsMember fgen:UnitedStatesAndRestOfWorldMember 2019-12-31 0000921299 us-gaap:AccountsReceivableMember 2020-03-31 0000921299 us-gaap:LeaseholdImprovementsMember 2020-03-31 0000921299 us-gaap:LeaseholdImprovementsMember 2019-12-31 0000921299 fgen:LaboratoryEquipmentMember 2020-03-31 0000921299 fgen:LaboratoryEquipmentMember 2019-12-31 0000921299 us-gaap:MachineryAndEquipmentMember 2020-03-31 0000921299 us-gaap:MachineryAndEquipmentMember 2019-12-31 0000921299 us-gaap:ComputerEquipmentMember 2020-03-31 0000921299 us-gaap:ComputerEquipmentMember 2019-12-31 0000921299 us-gaap:FurnitureAndFixturesMember 2020-03-31 0000921299 us-gaap:FurnitureAndFixturesMember 2019-12-31 0000921299 us-gaap:ConstructionInProgressMember 2020-03-31 0000921299 us-gaap:ConstructionInProgressMember 2019-12-31 0000921299 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0000921299 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0000921299 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-03-31 0000921299 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-03-31 0000921299 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0000921299 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0000921299 us-gaap:StockCompensationPlanMember srt:MinimumMember 2020-01-01 2020-03-31 0000921299 us-gaap:StockCompensationPlanMember srt:MinimumMember 2019-01-01 2019-03-31 0000921299 us-gaap:StockCompensationPlanMember srt:MaximumMember 2020-01-01 2020-03-31 0000921299 us-gaap:StockCompensationPlanMember srt:MaximumMember 2019-01-01 2019-03-31 0000921299 us-gaap:StockCompensationPlanMember 2020-01-01 2020-03-31 0000921299 us-gaap:StockCompensationPlanMember 2019-01-01 2019-03-31 0000921299 us-gaap:CollaborativeArrangementMember fgen:AstellasMember 2020-01-01 2020-03-31 0000921299 us-gaap:CollaborativeArrangementMember fgen:AstellasMember 2019-01-01 2019-03-31 0000921299 us-gaap:CollaborativeArrangementMember fgen:AstellasMember 2020-03-31 0000921299 us-gaap:CollaborativeArrangementMember fgen:AstellasMember 2019-12-31 0000921299 fgen:AstellasCollaborationAgreementMember fgen:AstellasMember country:JP 2020-03-31 0000921299 fgen:AstellasMember srt:EuropeMember 2020-03-31 0000921299 fgen:AstellasMember srt:EuropeMember 2019-12-31 0000921299 srt:EuropeMember 2020-03-31 0000921299 fgen:ManufactureAndSupplyOfRoxadustatMember 2020-03-31 0000921299 fgen:ResearchAndPreClinicalStageDevelopmentProgramsMember 2020-01-01 2020-03-31 0000921299 fgen:OtherPurchasesMember 2020-03-31

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2020

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                to                 

Commission file number: 001-36740

 

FIBROGEN, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

77-0357827

(State or Other Jurisdiction of

Incorporation or Organization)

 

(I.R.S. Employer

Identification No.)

 

409 Illinois Street

 

 

San Francisco, CA

 

94158

(Address of Principal Executive Offices)

 

(Zip Code)

(415) 978-1200

Registrant’s telephone number, including area code:

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, $0.01 par value

FGEN

The Nasdaq Global Select Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

 

 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.         

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2).    Yes      No  

The number of shares of common stock outstanding as of April 30, 2020 was 89,104,753.

 

 

 

 


 

FIBROGEN, INC.

TABLE OF CONTENTS

 

 

 

Page

PART I—FINANCIAL INFORMATION

 

 

 

 

 

 

Item 1.

Condensed Consolidated Financial Statements (Unaudited)

 

2

 

Condensed Consolidated Balance Sheets as of March 31, 2020 and December 31, 2019 (Unaudited)

 

2

 

Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2020 and 2019 (Unaudited)

 

3

 

Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2020 and 2019 (Unaudited)

 

4

 

Condensed Consolidated Statements of Changes in Equity for the Three Months Ended March 31, 2020 and 2019 (Unaudited)

 

5

 

Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2020 and 2019 (Unaudited)

 

6

 

Notes to the Condensed Consolidated Financial Statements (Unaudited)

 

7

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

21

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

 

35

Item 4.

Controls and Procedures

 

35

 

 

 

 

PART II—OTHER INFORMATION

 

 

 

 

 

 

Item 1.

Legal Proceedings

 

36

Item 1A.

Risk Factors

 

36

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

 

71

Item 3.

Defaults Upon Senior Securities

 

71

Item 4.

Mine Safety Disclosures

 

71

Item 5.

Other Information

 

71

Item 6.

Exhibits

 

72

 

Signatures

 

73

 

1


Table of Contents

 

 

FIBROGEN, INC.

PART I—FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share amounts)

(Unaudited)

 

 

 

March 31, 2020

 

 

December 31, 2019

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

121,560

 

 

$

126,266

 

Short-term investments

 

 

413,869

 

 

 

407,491

 

Accounts receivable, net ($3,723 and $4,845 from a related party)

 

 

58,540

 

 

 

28,455

 

Inventories

 

 

8,408

 

 

 

6,887

 

Prepaid expenses and other current assets ($126,558 and $125,210 from

    a related party)

 

 

134,028

 

 

 

133,391

 

Total current assets

 

 

736,405

 

 

 

702,490

 

 

 

 

 

 

 

 

 

 

Restricted time deposits

 

 

2,072

 

 

 

2,072

 

Long-term investments

 

 

223

 

 

 

61,118

 

Property and equipment, net

 

 

40,058

 

 

 

42,743

 

Finance lease right-of-use assets

 

 

37,017

 

 

 

39,602

 

Other assets

 

 

8,602

 

 

 

9,372

 

Total assets

 

$

824,377

 

 

$

857,397

 

 

 

 

 

 

 

 

 

 

Liabilities, stockholders’ equity and non-controlling interests

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

2,865

 

 

$

6,088

 

Accrued and other current liabilities ($92 and $36,883 to a related party)

 

 

42,309

 

 

 

83,816

 

Deferred revenue

 

 

8,531

 

 

 

490

 

Finance lease liabilities, current

 

 

12,396

 

 

 

12,351

 

Total current liabilities

 

 

66,101

 

 

 

102,745

 

 

 

 

 

 

 

 

 

 

Long-term portion of lease obligations

 

 

1,040

 

 

 

1,141

 

Product development obligations

 

 

16,536

 

 

 

16,780

 

Deferred revenue, net of current

 

 

139,404

 

 

 

99,449

 

Finance lease liabilities, non-current

 

 

34,545

 

 

 

37,610

 

Other long-term liabilities

 

 

89,122

 

 

 

64,266

 

Total liabilities

 

 

346,748

 

 

 

321,991

 

 

 

 

 

 

 

 

 

 

Commitments and Contingencies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued

   and outstanding at March 31, 2020 and December 31, 2019

 

 

 

 

 

 

Common stock, $0.01 par value; 225,000 shares authorized at March 31, 2020

   and December 31, 2019; 88,896 and 87,657 shares issued and outstanding at

  March 31, 2020 and December 31, 2019

 

 

889

 

 

 

877

 

Additional paid-in capital

 

 

1,319,354

 

 

 

1,300,725

 

Accumulated other comprehensive income (loss)

 

 

1,183

 

 

 

(747

)

Accumulated deficit

 

 

(863,068

)

 

 

(784,720

)

Total stockholders’ equity

 

 

458,358

 

 

 

516,135

 

Non-controlling interests

 

 

19,271

 

 

 

19,271

 

Total equity

 

 

477,629

 

 

 

535,406

 

Total liabilities, stockholders’ equity and non-controlling interests

 

$

824,377

 

 

$

857,397

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

2


Table of Contents

 

 

FIBROGEN, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2020

 

 

2019

 

Revenue:

 

 

 

 

 

 

 

 

License revenue

 

$

 

 

$

 

Development and other revenue (includes $4,737 and $4,859

   from a related party)

 

 

19,446

 

 

 

23,863

 

Product revenue, net

 

 

4,955

 

 

 

 

Total revenue

 

 

24,401

 

 

 

23,863

 

 

 

 

 

 

 

 

 

 

Operating costs and expenses:

 

 

 

 

 

 

 

 

Cost of goods sold

 

 

970

 

 

 

 

Research and development

 

 

54,902

 

 

 

50,496

 

Selling, general and administrative

 

 

49,603

 

 

 

22,210

 

Total operating costs and expenses

 

 

105,475

 

 

 

72,706

 

Loss from operations

 

 

(81,074

)

 

 

(48,843

)

 

 

 

 

 

 

 

 

 

Interest and other, net

 

 

 

 

 

 

 

 

Interest expense

 

 

(633

)

 

 

(770

)

Interest income and other, net

 

 

3,165

 

 

 

4,177

 

Total interest and other, net

 

 

2,532

 

 

 

3,407

 

 

 

 

 

 

 

 

 

 

Loss before income taxes

 

 

(78,542

)

 

 

(45,436

)

Benefit from income taxes

 

 

(194

)

 

 

(25

)

Net loss

 

$

(78,348

)

 

$

(45,411

)

 

 

 

 

 

 

 

 

 

Net loss per share - basic and diluted

 

$

(0.89

)

 

$

(0.53

)

 

 

 

 

 

 

 

 

 

Weighted average number of common shares used to calculate

   net loss per share - basic and diluted

 

 

88,219

 

 

 

85,704

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

3


Table of Contents

 

 

FIBROGEN, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands)

(Unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2020

 

 

2019

 

Net loss

 

$

(78,348

)

 

$

(45,411

)

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

Foreign currency translation adjustments

 

 

281

 

 

 

291

 

Available-for-sale investments:

 

 

 

 

 

 

 

 

Unrealized gain on investments, net of tax effect

 

 

1,649

 

 

 

442

 

Other comprehensive income, net of taxes

 

 

1,930

 

 

 

733

 

Comprehensive loss

 

$

(76,418

)

 

$

(44,678

)

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

 

4


Table of Contents

 

 

FIBROGEN, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(In thousands, except share data)

(Unaudited)

 

 

 

For The Three Month Period

 

 

 

Common Stock

 

 

Additional

Paid-in

 

 

Accumulated

Other

Comprehensive

 

 

Accumulated

 

 

Non

Controlling

 

 

 

 

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income (Loss)

 

 

Deficit

 

 

Interests

 

 

Total

 

Balance at December 31,

   2019

 

 

87,657,489

 

 

$

877

 

 

$

1,300,725

 

 

$

(747

)

 

$

(784,720

)

 

$

19,271

 

 

$

535,406

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(78,348

)

 

 

 

 

 

(78,348

)

Change in unrealized gain or

   loss on investments

 

 

 

 

 

 

 

 

 

 

 

1,649

 

 

 

 

 

 

 

 

 

1,649

 

Foreign currency translation

   adjustments

 

 

 

 

 

 

 

 

 

 

 

281

 

 

 

 

 

 

 

 

 

281

 

Shares issued from stock

   plans, net of payroll taxes

   paid

 

 

1,238,141

 

 

 

12

 

 

 

1,713

 

 

 

 

 

 

 

 

 

 

 

 

1,725

 

Stock-based compensation

 

 

 

 

 

 

 

 

16,916

 

 

 

 

 

 

 

 

 

 

 

 

16,916

 

Balance at March 31,

   2020

 

 

88,895,630

 

 

$

889

 

 

$

1,319,354

 

 

$

1,183

 

 

$

(863,068

)

 

$

19,271

 

 

$

477,629

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 31,

   2018

 

 

85,432,102

 

 

$

854

 

 

$

1,226,453

 

 

$

(2,281

)

 

$

(715,827

)

 

$

19,271

 

 

$

528,470

 

Impact of adoption of

   ASC 842

 

 

 

 

 

 

 

 

 

 

 

 

 

 

8,688

 

 

 

 

 

 

8,688

 

Impact of change in

   accounting principle upon

   adoption of ASU 2018-02

 

 

 

 

 

 

 

 

 

 

 

611

 

 

 

(611

)

 

 

 

 

 

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(45,411

)

 

 

 

 

 

(45,411

)

Change in unrealized gain or

   loss on investments

 

 

 

 

 

 

 

 

 

 

 

442

 

 

 

 

 

 

 

 

 

442

 

Foreign currency translation

   adjustments

 

 

 

 

 

 

 

 

 

 

 

291

 

 

 

 

 

 

 

 

 

291

 

Shares issued from stock

   plans, net of payroll taxes

   paid

 

 

697,462

 

 

 

7

 

 

 

(423

)

 

 

 

 

 

 

 

 

 

 

 

(416

)

Stock-based compensation

 

 

 

 

 

 

 

 

16,430

 

 

 

 

 

 

 

 

 

 

 

 

16,430

 

Balance at March 31,

   2019

 

 

86,129,564

 

 

$

861

 

 

$

1,242,460

 

 

$

(937

)

 

$

(753,161

)

 

$

19,271

 

 

$

508,494

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

5


Table of Contents

 

 

FIBROGEN, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2020

 

 

2019

 

Operating activities

 

 

 

 

 

 

 

 

Net loss

 

$

(78,348

)

 

$

(45,411

)

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

 

 

 

 

 

 

 

 

Depreciation

 

 

2,868

 

 

 

2,744

 

Amortization of finance lease right-of-use assets

 

 

2,594

 

 

 

2,569

 

Net accretion of discount on investments

 

 

(143

)

 

 

(1,350

)

Unrealized loss (gain) on equity investments

 

 

21

 

 

 

(51

)

Gain on disposal of property and equipment

 

 

 

 

 

(10

)

Stock-based compensation

 

 

16,916

 

 

 

16,430

 

Tax benefit on unrealized gain on available-for-sale securities

 

 

(439

)

 

 

(118

)

Realized loss on sales of available-for-sale securities

 

 

258

 

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable, net

 

 

(30,085

)

 

 

57,661

 

Inventories

 

 

(1,521

)

 

 

 

Prepaid expenses and other current assets

 

 

(637

)

 

 

(2,785

)

Other assets

 

 

761

 

 

 

(51

)

Accounts payable

 

 

(3,223

)

 

 

(5,367

)

Accrued and other liabilities

 

 

(41,224

)

 

 

736

 

Deferred revenue

 

 

47,996

 

 

 

(2,580

)

Accrued interest for finance lease liabilities

 

 

(216

)

 

 

219

 

Other long-term liabilities

 

 

24,936

 

 

 

(156

)

Net cash provided by (used in) operating activities

 

 

(59,486

)

 

 

22,480

 

 

 

 

 

 

 

 

 

 

Investing activities

 

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(459

)

 

 

(483

)

Purchases of available-for-sale securities and term deposit

 

 

(38

)

 

 

(76,004

)

Proceeds from sales of available-for-sale securities

 

 

10,606

 

 

 

 

Proceeds from maturities of investments

 

 

45,900

 

 

 

50,000

 

Net cash provided by (used in) investing activities

 

 

56,009

 

 

 

(26,487

)

 

 

 

 

 

 

 

 

 

Financing activities

 

 

 

 

 

 

 

 

Repayments of finance lease liabilities

 

 

(2,814

)

 

 

(3,017

)

Repayments of lease obligations

 

 

(101

)

 

 

(101

)

Cash paid for payroll taxes on restricted stock unit releases

 

 

(5,279

)

 

 

(5,988

)

Proceeds from issuance of common stock

 

 

7,004

 

 

 

5,572

 

Net cash used in financing activities

 

 

(1,190

)

 

 

(3,534

)

Effect of exchange rate change on cash and cash equivalents

 

 

(39

)

 

 

(44

)

Net decrease in cash and cash equivalents

 

 

(4,706

)

 

 

(7,585

)

Total cash and cash equivalents at beginning of period

 

 

126,266

 

 

 

89,258

 

Total cash and cash equivalents at end of period

 

$

121,560

 

 

$

81,673

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

 

6


Table of Contents

 

 

FIBROGEN, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1.

Significant Accounting Policies

Description of Operations

FibroGen, Inc. (“FibroGen” or the “Company”) was incorporated in 1993 in Delaware and are headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People’s Republic of China (“China”). FibroGen is a leading biopharmaceutical company developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (“HIF”), connective tissue growth factor (“CTGF”) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Roxadustat, FibroGen’s most advanced product, is an oral small molecule inhibitor of HIF prolyl hydroxylase (“HIF-PH”) activity that has received marketing authorization in China for the treatment of anemia caused by chronic kidney disease (“CKD”) in dialysis and non-dialysis patients. Evrenzo® (roxadustat) is also approved in Japan for the treatment of anemia associated with CKD in dialysis patients. In January 2020, Astellas Pharma Inc. (“Astellas”) submitted a supplemental New Drug Application (“NDA”) in Japan for the treatment of anemia in non-dialysis CKD patients.

The Company’s NDA filing in the United States (“U.S.”) for roxadustat for the treatment of anemia in dialysis and non-dialysis CKD patients was accepted by the U.S. Food and Drug Administration (“FDA”) in February 2020. In Europe, the Marketing Authorization Application (“MAA”) filing with the European Medicines Agency (“EMA”) is expected in the second quarter of 2020 for CKD in both dialysis and non-dialysis.

Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (“MDS”). Roxadustat is in Phase 2 clinical development for chemotherapy-induced anemia.

Pamrevlumab, an anti-CTGF human monoclonal antibody, is in Phase 3 clinical development for the treatment of both idiopathic pulmonary fibrosis (“IPF”) and pancreatic cancer. Pamrevlumab is also currently in a Phase 2 trial for Duchenne muscular dystrophy (“DMD”).

Basis of Presentation and Principles of Consolidation

The condensed consolidated financial statements include the accounts of FibroGen, its wholly owned subsidiaries and its majority-owned subsidiaries, FibroGen Europe Oy and FibroGen China Anemia Holdings, Ltd. (“FibroGen China”). All inter-company transactions and balances have been eliminated in consolidation. The Company operates as one segment — the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs.

The unaudited condensed consolidated financial statements and related disclosures have been prepared in accordance with accounting principles generally accepted in the U.S. (“U.S. GAAP”) applicable to interim financial reporting and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U.S. Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and footnote disclosures normally included in the annual consolidated financial statements. The financial information included herein should be read in conjunction with the consolidated financial statements and related notes in the Company’s Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2019 (“2019 Form 10-K”).

Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions include valuation and recognition of revenue. On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates. In the Company’s opinion, the accompanying unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair statement of its financial position, results of operations and cash flows for the interim periods presented.

7


Table of Contents

 

 

Net Loss per Share

Diluted weighted average shares did not include 8.7 million and 9.5 million securities for the three months March 31, 2020 and 2019, as they were anti-dilutive.

Risks and Uncertainties

The Company’s business is subject to risks and uncertainties, including those related to the severe acute respiratory syndrome coronavirus 2 and the associated disease (“COVID-19”) and the related shelter-in-place, stay-at-home and other similar governmental orders issued in response to the COVID-19 pandemic. 

In the first quarter of 2020, the Company experienced slower enrollment in its clinical trials due to the interruption caused by COVID-19 in the normal worldwide healthcare system, as well as an impact on its roxadustat sales in China due to the social distancing and other restrictions put in place, particularly during February and March. The future impact of the COVID-19 pandemic on the Company’s business is highly uncertain and difficult to predict. The COVID-19 pandemic may continue to affect enrollment in and initiation of the Company’s clinical trials, and could affect the Company’s supply chain if further social distancing and other business restrictions are put in place by various government entities, particularly in China and the U.S. COVID-19 may affect the health of the Company’s employees limiting the Company’s productivity. The COVID-19 pandemic may also impact the market for the Company’s products and product candidates in the future, affecting sales of the Company’s products. Such possible risks and uncertain impacts from the COVID-19 pandemic could have a material adverse effect on the Company’s drug development, commercialization revenues, and other portions of its business, and in particular, could impact the Company’s assumptions of accounts receivable collectability, fair value measurements of investments, liquidity, and development costs. The extent of the pandemic’s effect on our operational and financial performance will depend in large part on future developments, particularly with respect to the scope and severity of the pandemic, governmental restrictions put in place to fight the pandemic, and the development of vaccines and treatments for COVID-19. Due to the inherent uncertainty of the unprecedented and rapidly evolving situation, we are unable to estimate the likely impact of the COVID-19 pandemic on our future operations.

Recently Issued and Adopted Accounting Guidance

In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. This guidance requires capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This guidance was effective for annual reporting periods beginning after December 15, 2019, including interim periods. The Company adopted this guidance on January 1, 2020 using the prospective method, and the adoption of this guidance did not have material impact to the Company’s consolidated financial statements.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). This guidance is intended to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. This guidance requires the measurement of financial assets with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. This guidance requires an impairment model, known as the current expected credit loss model, which is based on expected losses rather than incurred losses. Entities are required to carry an allowance for expected credit losses for financial assets, including most debt instruments (except those carried at fair value) and trade receivables. In November 2019, the FASB issued ASU No. 2019-11, Codification Improvements to Topic 326, Financial Instruments-Credit Losses (“ASU 2019-11”), which has the same effective dates and transition requirements as ASU 2016-13. ASU 2016-13 and ASU 2019-11 were effective for annual reporting periods beginning after December 15, 2019 including interim periods. The Company’s investment portfolio primarily consists of U.S. Treasury bills and notes carried at fair value, which is required to follow the impairment model under Topic 326. The Company adopted this guidance on January 1, 2020. Based on the composition of the Company’s trade receivables and investment portfolio, economic conditions and historical credit loss activity, the adoption of this guidance did not have material impact to the Company’s consolidated financial statements.

8


Table of Contents

 

 

Recently Issued Accounting Guidance Not Yet Adopted

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. This guidance simplifies the accounting for income taxes by clarifying and amending existing guidance related to the recognition of franchise tax, the evaluation of a step up in the tax basis of goodwill, and the effects of enacted changes in tax laws or rates in the effective tax rate computation, among other clarifications. This guidance is effective for annual reporting periods beginning after December 15, 2020 including interim periods, with early adoption permitted. The Company does not plan to early adopt this guidance and does not anticipate a material impact to its consolidated financial statements upon adoption of this guidance.

Significant Accounting Policies

The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the 2019 Form 10-K, except for the following:

Trade accounts receivable

The allowance for doubtful accounts is based on the Company’s assessment of the collectability of customer accounts. The Company makes estimates of expected credit losses for the allowance for doubtful accounts by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, current economic and regulatory conditions that may affect a customer’s ability to pay, and estimates of expected future losses. The Company’s bad debt expense for the three months ended March 31, 2020 and the allowance for doubtful accounts as of March 31, 2020 were immaterial.

Credit losses – Available-for-sale debt securities

The Company periodically assesses its available-for-sale investments for other-than-temporary impairment. For debt securities in an unrealized loss position, the Company first considers its intent to sell, or whether it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis. If either of these criteria are met, the amortized cost basis of such debt securities is written down to fair value through interest and other, net.

For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in the fair value of such debt securities has resulted from credit losses or other factors. The Company considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and any adverse conditions specifically related to the securities, among other factors. If this assessment indicates that a credit loss may exist, the Company then compares the present value of cash flows expected to be collected from such securities to their amortized cost basis. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded through interest and other, net, limited by the amount that the fair value is less than the amortized cost basis. Any additional impairment not recorded through an allowance for credit losses is recognized in other comprehensive income.

Changes in the allowance for credit losses are recorded as provision for, or reversal of, credit loss expense. Losses are charged against the allowance when the Company believes the uncollectability of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met.

2.

Collaboration Agreements

Astellas Agreements

Japan Agreement

In June 2005, the Company entered into a collaboration agreement with Astellas for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in Japan (“Japan Agreement”). Under this agreement, Astellas paid license fees and other consideration totaling $40.1 million (such amounts were fully received as of February 2009). Under the Japan Agreement, the Company is also eligible to receive from Astellas an aggregate of approximately $132.5 million in potential milestone payments, comprised of (i) up to $22.5 million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of July 2016), (ii) up to $95.0 million in milestone payments upon achievement of specified regulatory milestone events, and (iii) up to approximately $15.0 million in milestone payments upon the achievement of specified commercial sales milestone. The Japan Agreement also provides for tiered payments based on net sales of product (as defined) in the low 20% range after commercial launch. The aggregate amount of consideration received through March 31, 2020 totals $90.1 million. 

9


Table of Contents

 

 

Europe Agreement

In April 2006, the Company entered into a separate collaboration agreement with Astellas for the development and commercialization of roxadustat for the treatment of anemia in Europe, the Middle East, the Commonwealth of Independent States and South Africa (“Europe Agreement”). Under the terms of the Europe Agreement, Astellas paid license fees and other upfront consideration totaling $320.0 million (such amounts were fully received as of February 2009). The Europe Agreement also provides for additional development and regulatory approval milestone payments up to $425.0 million, comprised of (i) up to $90.0 million in milestone payments upon achievement of specified clinical and development milestone events (such amounts were fully received as of 2012), (ii) up to $335.0 million in milestone payments upon achievement of specified regulatory milestone events. Under the Europe Agreement, Astellas committed to fund 50% of joint development costs for Europe and North America, and all territory-specific costs. The Europe Agreement also provides for tiered payments based on net sales of product (as defined) in the low 20% range. The aggregate amount of consideration received through March 31, 2020 totals $410.0 million.

During the second quarter of 2019, the Company received positive topline results from analyses of pooled major adverse cardiac event (“MACE”) and MACE+ data from its Phase 3 trials evaluating roxadustat as a treatment for dialysis and non-dialysis CKD patients, enabling Astellas to prepare for an MAA submission to the EMA, following the Company’s NDA submission to the FDA. These milestones became probable of being achieved in the second quarter of 2019, and the total consideration of $130.0 million associated with these milestones was included in the transaction price and allocated to performance obligations under the Europe Agreement in the second quarter of 2019, of which $128.8 million was recognized as revenue during 2019, and $0.3 million was recognized as revenue during the three months ended March 31, 2020, from performance obligations satisfied or partially satisfied. According to the Europe Agreement, these milestone payments are not billable to Astellas until the submission of an MAA, which is expected in the second quarter of 2020. Therefore this $130.0 million remained as an unbilled contract asset as of March 31, 2020.

AstraZeneca Agreements

U.S./Rest of World (“RoW”) Agreement

Effective July 30, 2013, the Company entered into a collaboration agreement with AstraZeneca AB (“AstraZeneca”) for the development and commercialization of roxadustat for the treatment of anemia in the U.S. and all other countries in the world, other than China, not previously licensed under the Astellas Europe and Astellas Japan Agreements (“U.S./RoW Agreement”). It also excludes China, which is covered by a separate agreement with AstraZeneca described below. Under the terms of the U.S./RoW Agreement, AstraZeneca paid upfront, non-contingent, non-refundable and time-based payments totaling $374.0 million (such amounts were fully received as of June 2016). Under the U.S./RoW Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $875.0 million in potential milestone payments, comprised of (i) up to $65.0 million in milestone payments upon achievement of specified clinical and development milestone events, $15.0 million of which was received in 2015 as a result of the finalization of its two audited pre-clinical carcinogenicity study reports, and the remaining $50.0 million was received in April 2020 as a result of the NDA submission milestone, (ii) up to $325.0 million in milestone payments upon achievement of specified regulatory milestone events, (iii) up to $160.0 million in milestone payments related to activity by potential competitors and (iv) up to approximately $325.0 million in milestone payments upon the achievement of specified commercial sales events. The aggregate amount of consideration received through March 31, 2020 totals $389.0 million. 

As mentioned above, during the second quarter of 2019, the Company received positive topline results from analyses of pooled MACE and MACE+ data from its Phase 3 trials for roxadustat, enabling the Company’s NDA submission to the FDA. The regulatory milestone payment associated with this NDA submission became probable of being achieved in the second quarter of 2019. Accordingly, the consideration of $50.0 million associated with this milestone was included in the transaction price and allocated to performance obligations under the U.S./ RoW Agreement in the second quarter of 2019, of which $42.4 million was recognized as revenue during 2019, and $0.2 million was recognized as revenue during the three months ended March 31, 2020, from performance obligations satisfied or partially satisfied. The Company submitted such NDA in December 2019, which was accepted by the FDA for review in February 2020. According to the U.S/RoW Agreement, this milestone payment is billable to AstraZeneca when the NDA is accepted by the FDA. Therefore this $50.0 million was billed during the first quarter of 2020, the payment of which was fully received in April 2020.

10


Table of Contents

 

 

China Agreement

Effective July 30, 2013, the Company (through its subsidiaries affiliated with China) entered into a collaboration agreement with AstraZeneca for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in China (“China Agreement”). Under the terms of the China Agreement, AstraZeneca agreed to pay upfront consideration totaling $28.2 million (such amounts were fully received in 2014). Under the China Agreement, the Company is also eligible to receive from AstraZeneca an aggregate of approximately $348.5 million in potential milestone payments, comprised of (i) up to $15.0 million in milestone payments upon achievement of specified clinical and development milestone events, (ii) up to $146.0 million in milestone payments upon achievement of specified regulatory milestone events, and (iii) up to approximately $187.5 million in milestone payments upon the achievement of specified commercial sales and other events. The China Agreement is structured as a 50/50 profit or loss share (as defined) and provides for joint development costs (including capital and equipment costs for construction of the manufacturing plant in China), to be shared equally during the development. The aggregate amount of such consideration received through March 31, 2020 totals $77.2 million.

In December 2019, roxadustat was included on the updated National Reimbursement Drug List (“NRDL”) released by China’s National Healthcare Security Administration (“NHSA”) for the treatment of anemia in CKD, covering patients who are non-dialysis dependent as well as those who are dialysis-dependent. The inclusion on the NRDL triggered a total of $22.0 million milestones payable to the Company by AstraZeneca. Accordingly, the total consideration of $22.0 million associated with these milestones was included in the transaction price and allocated to performance obligations under the China Agreement during fourth quarter of 2019. This milestone payment was received during the first quarter of 2020.

AstraZeneca and Astellas approved the development of roxadustat for the treatment of chemotherapy-induced anemia (“CIA”) in December 2018 and January 2019, respectively. Costs associated with the development of this indication are expected to be shared 50/50 between AstraZeneca and Astellas. In addition, in December 2018, anemia of chronic inflammation (“ACI”) and multiple myeloma (“MM”) was approved for development by AstraZeneca and is expected to be fully funded by them. For revenue recognition purposes, the Company concluded that the addition of these new indications represents a modification to the collaboration agreements and will be accounted for separately, meaning the development costs associated with the new indications are distinct from the original development costs. The development service period for roxadustat for the treatment of CIA, ACI and MM under the AstraZeneca agreements is estimated to continue through the end of 2024, to allow for development of these additional indications.

Summary of Revenue Recognized Under the Collaboration Agreements

The table below summarizes the accounting treatment for the various performance obligations pursuant to each of the Astellas and AstraZeneca agreements. License amounts identified below are included in the “License revenue” line item in the condensed consolidated statements of operations. All other elements identified below are included in the “Development and other revenue” line item in the condensed consolidated statements of operations.

Amounts recognized as revenue under the Japan Agreement were as follows (in thousands): 

 

 

 

 

 

Three Months Ended March 31,

 

Agreement

 

Performance Obligation

 

2020

 

 

2019

 

Japan

 

License revenue

 

$

 

 

$

 

 

 

Development revenue

 

$

163

 

 

$

246

 

 

The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Japan Agreement, along with any associated deferred revenue as follows (in thousands):

 

Japan Agreement

 

Cumulative

Revenue

Through

March 31, 2020

 

 

Deferred

Revenue at

March 31, 2020

 

 

Total

Consideration

Through

March 31, 2020

 

License

 

$

86,024

 

 

$

 

 

$

86,024

 

Development revenue

 

 

15,293

 

 

 

269

 

 

 

15,562

 

Total license and development revenue

 

$

101,317

 

 

$

269

 

 

$

101,586

 

The revenue recognized under the Japan Agreement for the three months ended March 31, 2020 included an increase in revenue of $0.1 million resulting from changes to estimated variable consideration in the current period relating to performance obligations satisfied or partially satisfied in previous periods. The remainder of the transaction price related to the Japan Agreement includes no further variable consideration from estimated future co-development billing.

11


Table of Contents

 

 

Amounts recognized as revenue under the Europe Agreement were as follows (in thousands):

 

 

 

 

 

Three Months Ended March 31,

 

Agreement

 

Performance Obligation

 

2020

 

 

2019

 

Europe

 

License revenue

 

$

 

 

$

 

 

 

Development revenue

 

$

4,574

 

 

$

4,613

 

 

The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Europe Agreement, along with any associated deferred revenue as follows (in thousands):

 

Europe Agreement

 

Cumulative

Revenue

Through

March 31, 2020

 

 

Deferred

Revenue at

March 31, 2020

 

 

Total

Consideration

Through

March 31, 2020

 

License

 

$

487,951

 

 

$

 

 

$

487,951

 

Development revenue

 

 

235,582

 

 

 

3,442

 

 

 

239,024

 

Total license and development revenue

 

$

723,533

 

 

$

3,442

 

*

$

726,975

 

_______________________________________________________________________________________________________

*

Contract assets and liabilities related to rights and obligations in the same contract are recorded net on the condensed consolidated balance sheets. As of March 31, 2020, prepaid expenses and other current assets included a net unbilled contract asset of $126.6 million related to the Europe Agreement, which represents the net of the above-mentioned unbilled contract asset of $130.0 million, and $3.4 million of deferred revenue presented above.

The revenue recognized under the Europe Agreement for the three months ended March 31, 2020 included an increase in revenue of $0.9 million resulting from changes to estimated variable consideration in the current period relating to performance obligations satisfied or partially satisfied in previous periods. The remainder of the transaction price related to the Europe Agreement includes $38.2 million of variable consideration from estimated future co-development billing and is expected to be recognized over the remaining development service period.

Amounts recognized as revenue under the U.S./RoW Agreement were as follows (in thousands):

 

 

 

 

 

Three Months Ended March 31,

 

Agreement

 

Performance Obligation

 

2020

 

 

2019

 

U.S. / RoW

and China

 

License revenue

 

$

 

 

$

 

 

 

Development revenue

 

 

14,556

 

 

 

19,004

 

 

 

China performance obligation

 

$

153

 

 

$

 

 

The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the U.S./RoW Agreement and China Agreement, along with any associated deferred revenue as follows (in thousands):

 

U.S. / RoW and China Agreements

 

Cumulative

Revenue

Through

March 31, 2020

 

 

Deferred

Revenue at

March 31, 2020

 

 

Total

Consideration

Through

March 31, 2020

 

License

 

$

341,844

 

 

$

 

 

$

341,844

 

Co-development, information sharing &

  committee services

 

 

507,822

 

 

 

6,323

 

 

 

514,145

 

China performance obligation

 

 

243

 

 

 

141,079

 

 

 

141,322

 

Total license and development revenue

 

$

849,909

 

 

$

147,402

 

 

$

997,311

 

 

12


Table of Contents

 

 

The revenue recognized under the U.S./RoW Agreement for the three months ended March 31, 2020 included an insignificant decrease in revenue resulting from changes to estimated variable consideration in the current period relating to performance obligations satisfied or partially satisfied in previous periods. The remainder of the transaction price related to the U.S./RoW Agreement and China Agreement includes $115.3 million of variable consideration from estimated future co-development billing and is expected to be recognized over the remaining development service period, except for amounts allocated to the China performance obligation, which are expected to be recognized in a pattern consistent with estimated deliveries of the commercial drug product.

Product Revenue, Net

The Company started commercial sales of roxadustat drug product in China in the third quarter of 2019. Drug product revenue is recognized in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those products, net of price adjustment, contractual sales rebate and other discounts. Product revenue, net was as follows (in thousands):

 

 

 

Three Months Ended March 31, 2020

 

Gross revenue

 

$

5,372

 

Contractual sales rebate

 

 

(376

)

Key account hospital sales rebate

 

 

(27

)

Transfer fee discount

 

 

(14

)

Product revenue, net

 

$

4,955

 

 

For the three months ended March 31, 2020, the contractual sales rebate was $0.4 million, which was calculated based on the stated percentage of gross sales by each distributor in the distribution agreement entered between FibroGen and each distributor. All other rebates including sales return allowance were immaterial for the period.

The following table is a roll-forward of accounts receivable allowances related to product revenue:

 

 

 

Balance at December 31, 2019

 

 

Current Period Additions

 

 

Credits / Payments

 

 

Balance at March 31, 2020

 

Price adjustment

 

$

936

 

 

$

 

 

$

 

 

$

936

 

Contractual sales rebate

 

 

148

 

 

 

376

 

 

 

 

 

 

524

 

Key account hospital sales rebate

 

 

12

 

 

 

27

 

 

 

 

 

 

39

 

Transfer fee discount

 

 

6

 

 

 

14

 

 

 

 

 

 

20

 

Total

 

$

1,102

 

 

$

417

 

 

$

 

 

$

1,519

 

The above contractual allowances are recorded as reductions of the gross accounts receivable from the distributor in the same period that the related revenue is recorded, and applied to future sales orders made by the distributor under the Company’s discretion.

Other Revenues

Other revenues consist primarily of collagen material sold for research purposes. Other revenues were immaterial for all periods presented.

Deferred Revenue

Deferred revenue represents amounts billed, or in certain cases, yet to be billed to the Company’s collaboration partners for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount to be recognized within one year from the balance sheet date based on the estimated performance period of the underlying performance obligations. The long-term portion of deferred revenue represents amounts to be recognized after one year through the end of the non-contingent performance period of the underlying performance obligations.

Deferred revenue includes amounts allocated to the China unit of accounting under the AstraZeneca arrangement as revenue recognition associated with this unit of accounting is tied to the commercial launch of the products within China. As of March 31, 2020, approximately $1.7 million of the related deferred revenue was included in short-term deferred revenue, which represents the amount of deferred revenue associated with the China unit of accounting that is expected to be recognized within the next 12 months, as a result of the transfer of control of commercial drug product in China.

13


Table of Contents

 

 

3.

Fair Value Measurements

The fair values of the Company’s financial assets that are measured on a recurring basis are as follows (in thousands):

 

 

 

March 31, 2020

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

U.S. treasury notes and bills

 

$

303,265

 

 

$

80,489

 

 

$

 

 

$

383,754

 

Equity investments

 

 

223

 

 

 

 

 

 

 

 

 

223

 

Money market funds

 

 

72,148

 

 

 

 

 

 

 

 

 

72,148

 

Certificate of deposit

 

 

 

 

 

30,115

 

 

 

 

 

 

30,115

 

Total

 

$

375,636

 

 

$

110,604

 

 

$

 

 

$

486,240

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2019

 

 

 

Level 1

 

 

Level 2

 

 

Level 3